You are here

  • Home
  • Archive
  • Volume 1, Issue Suppl 1
  • Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: results of Phase I/IIa safety and feasibility study
Free

 

Online download statistics by month:

Online download statistics by month: December 2019 to April 2025

AbstractFullPdf
Dec 2019010
Jan 2020031
Feb 2020031
Mar 2020011
Apr 2020011
May 2020090
Jun 20200750
Jul 2020040
Aug 2020041
Sep 2020081
Oct 2020011
Nov 2020060
Dec 2020051
Jan 2021032
Feb 2021043
Mar 2021030
Apr 2021050
May 2021010
Jun 2021070
Jul 2021040
Aug 2021010
Sep 2021035
Oct 2021031
Nov 2021040
Dec 2021070
Jan 20220122
Feb 2022042
Mar 2022044
Apr 2022083
May 20220209
Jun 20220176
Jul 2022091
Aug 20220103
Sep 20220136
Oct 20220133
Nov 202201310
Dec 2022061
Jan 2023033
Feb 20230260
Mar 2023032
May 2023011
Jun 2023030
Jul 2023014
Aug 2023012
Sep 2023041
Oct 2023031
Nov 2023051
Dec 2023052
Jan 2024081
Feb 20240122
Mar 20240469
Apr 2024088
May 2024062
Jun 2024066
Jul 20240131
Aug 2024021
Sep 2024081
Oct 20240154
Nov 2024031
Dec 2024066
Jan 20250168
Feb 2025041
Mar 2025027
Apr 20250137
Total0476211